RACHEL HAKEMI: Open Payments
NPI 1518720432 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$735 in 34 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $467 · 2025 $735
Food & beverage: $647Education: $88
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 11 | $272 |
| Biogen, Inc. | 4 | $83 |
| Organon LLC | 2 | $56 |
| MILLICENT US INC | 3 | $55 |
| Exeltis, USA Inc. | 3 | $47 |
| Hologic Sales and Service, LLC | 1 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Exact Sciences Corporation | 2 | $33 |
| SHIELD THERAPEUTICS INC | 1 | $21 |
| Kerecis Limited | 1 | $20 |
Products named: Veozah, ZURZUVAE, NEXPLANON, FEMLYV, SLYND, Sonata Sonography-Guided Transcervical Fibroid Ablation System, MYFEMBREE, ACCRUFER.
Industry payments across IN — which companies pay providers there.
